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Abstract 
A simple, rapid and stability-indicating reversed-phase liquid chromatographic 
method was developed for the assay of varenicline tartrate (VRT) in the 
presence of its degradation products generated from forced decomposition 
studies. The HPLC separation was achieved on a C18 Inertsil column (250 mm 
x 4.6 mm i.d. particle size is 5 µm) employing a mobile phase consisting of 
ammonium acetate buffer containing trifluoroacetic acid (0.02M; pH 4) and 
acetonitrile in gradient program mode with a flow rate of 1.0 mL min
−1. The UV 
detector was operated at 237 nm while column temperature was maintained at 
40 °C. The developed method was validated as per ICH guidelines with respect 
to specificity, linearity, precision, accuracy, robustness and limit of quanti-
fication. The method was found to be simple, specific, precise and accurate. 
Selectivity of the proposed method was validated by subjecting the stock 
solution of VRT to acidic, basic, photolysis, oxidative and thermal degradation. 
The calibration curve was found to be linear in the concentration range of   
0.1–192 µg mL
−1  (R
2  = 0.9994). The peaks of degradation products did not 
interfere with that of pure VRT. The utility of the developed method was 
examined by analyzing the tablets containing VRT. The results of analysis were 
subjected to statistical analysis. 
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Introduction 
Varenicline (VRT) chemically known as (6R,10S)-7,8,9,10-tetrahydro-6H-6,10-methano-
pyrazino[2,3-h][3]benzazepine 2,3-dihydroxybutanedioate (1:1 salt, Fig. 1) was approved 
by US FDA as an aid to smoking cessation treatment [1–6]. It is a partial agonist and binds 
with high affinity and selectivity at α4β2 nAchR. It is used for the treatment of tobacco 
addiction [7–11]. Both nicotine and VRT bind to this receptor subtype. VRT blocks the 
ability  of  nicotine  to  activate  α4β2  receptors and thus to stimulate the central nervous 
mesolimbic dopamine system, believed to be the neuronal mechanism underlying 
reinforcement and reward experience upon smoking [12].  
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Fig. 1.   Structure of Varenicline tartrate (VRT) 
Literature survey revealed a radiometric HPLC method for the analysis of VRT metabolism 
in  in vivo  and  in vitro  [13] and a stability-indicating HPLC method [14]. The reported 
method [14] has narrow linearity range (2–14 µg mL
−1) and uses a high concentration of 
phosphate buffer (0.05 M) for elution. Further, it has poor system suitability parameters. In 
view of this, we have  developed a sensitive HPLC method that overcomes the above 
limitations for quantitative determination of VRT in bulk sample and formulations. Further, 
stress studies on VRT were carried out. The added advantage of the proposed method is 
its specificity as  it can be determined in the presence of its degradation products, 
excipients and additives.  
Experimental 
Chemicals and Reagents 
Pure VRT was the kind gift from Pfizer Ltd, India. HPLC grade acetonitrile and trifluoro-
acetic acid was purchased from spectrochem, India. Ammonium acetate, hydrochloric 
acid, sodium hydroxide and hydrogen peroxide were obtained from Merck (Darmstadt, 
Germany). Water obtained from a Milli-Q water purification system (Millipore, MA, USA) 
was used throughout the study. 
Instrumentation 
All HPLC measurements were made on a Waters 2695 separation module equipped with 
photo diode array detector 2996 module with data processing on Empower 2.0 version 
software. pH measurements were made on a pre-calibrated seven multi pH meter (Mettler 
Toledo Schwerzenbach, Switzerland). Mobile phase and sample/standard preparation 
were degassed using a sonicator (S. V. Scientific, India).  
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Procedures 
Preparation of Stock and Standard Solutions of VRT 
A stock solution of VRT (1.0 mg/mL) was prepared in the diluent (water:acetonitrile, 1:1 
v/v). Standard solutions of the drug were prepared by suitable dilution. 
Analysis of Pharmaceutical Formulation 
Ten tablets of VRT were finely powdered. An amount equivalent to 10 mg of the drug was 
weighed accurately and transferred into a 100 mL beaker. Using a mechanical stirrer, the 
powder was completely disintegrated in the mobile phase. The solution was filtered and 
the filtrate was made up to 10 mL with the mobile phase. It was further diluted for analysis. 
Validation of the Method  
After method development, the validation of the current method was established as per the 
guidelines of ICH and USP. 
Linearity and Range 
To establish the linearity range, the standard solutions (10 µL) were injected in triplicate 
into  the HPLC column and chromatograms were recorded.  The peak area versus 
concentration data was treated by least-squares linear regression analysis.  Typical 
chromatogram for VRT is shown in Fig. 2. The % RSD values were calculated. 
 
Fig. 2.   A typical chromatogram of VRT 
Precision 
Intra-day precision and inter-day precision were evaluated by analyzing six replicates of 
three different concentrations of the drug (50, 100 and 150 µg mL
−1) on the same day and 
on different days, respectively. The respective %RSD values were calculated.  
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Accuracy 
The accuracy of the assay method was evaluated by analyzing six replicates of three 
different concentrations of the drug (50, 100 and 150 µg mL
−1).  Further, it was also 
evaluated by fortifying a mixture of formulation sample with three known concentrations of 
the drug. The recovery of the added drug was determined. 
Specificity and Selectivity 
Specificity was established through the study of resolution factors of the drug peak from 
the nearest resolving peak and also among all other peaks. Further, the interference from 
excipients, impurities and degraded products on the assay of VRT was also examined.  
LOD and LOQ 
The LOD and LOQ were determined at a signal to noise ratio of 3:1 and 10:1, respectively, 
by injecting a series of test solutions of known concentrations within the linearity range. 
Precision study was also carried out at the LOQ level by injecting six pharmaceutical 
preparations. 
Robustness 
To  determine the robustness of the developed method, experimental conditions were 
deliberately altered to check the reproducibility and quantitative recovery of the drug. This 
was carried out by maintaining the flow rate of the mobile phase in the range of   
0.8–1.2 mL min
−1 and column temperature in the range of 35–45 °C. Chromatograms were 
recorded and compared with those obtained under optimum chromatographic conditions, 
mentioned earlier.  
Solution Stability and Mobile Phase Stability 
The solution stability of VRT in the assay method was carried out by leaving both the test 
solutions of the sample and reference standard in tightly capped volumetric flasks 
separately, at room temperature, up to the study period of 48 h. The chromatograms of 
these solutions were recorded separately with an interval of 1 h up to 48 h and the peak 
responses were compared.  
The mobile phase stability was carried out by assaying the freshly prepared bulk drug and 
formulation sample solutions against freshly prepared reference standard solution with an 
interval of 8 h.  The same mobile phase was used  throughout the experiment. %RSD 
values were calculated for mobile phase and solution stability experiments. 
Forced degradation study 
Forced degradation of the drug substance helps to establish the degradation pathways 
and the intrinsic stability of the drug. For this, the following experiments were carried out: 
Oxidation of VRT 
To study the oxidation of VRT, a 10.0 mL of stock solution of VRT (100 µg mL
−1) was 
transferred to 20 mL amber colored volumetric flask and the volume was made up to 
20 mL with 10% hydrogen peroxide. The flask was placed at 80 °C for 8 h, cooled to room 
temperature and the volume was readjusted with 10% hydrogen peroxide. Then the   Stress Degradation Studies on Varenicline Tartrate and Development of a Validated …  119 
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solution was filtered through a 0.45 µm syringe filter and 10 µL was injected into the liquid 
chromatographic system to detect the peak of degradant of the drug. 
Thermal degradation of VRT 
For this, 10.0 mL of VRT solution (100 µg mL
−1) was transferred in to a 20 mL volumetric 
flask and diluted to the mark with mobile phase. The flask was closed and placed at 80 °C 
for 8 h, cooled to room temperature and volume of solution was readjusted with diluent. 
Chromatogram was recorded.  
Degradation of VRT by Acid  
For this, 10.0 mL of VRT solution (100 µg mL
−1) was transferred into a 20 mL volumetric 
flask and the volume was made up to the mark with 1 M hydrochloric acid. The flask was 
placed at 80 °C for 8 h, cooled to room temperature and the volume was readjusted to 
20 mL with 1 M hydrochloric acid. The solution was adjusted to neutral pH using 1 M 
sodium hydroxide and injected into the liquid chromatograph and chromatogram was 
recorded.  
Degradation of VRT by Alkali  
This was conducted by transferring 10.0 mL of VRT solution (100 µg mL
−1) into a 20.0 mL 
volumetric flask and diluted to the mark with 1 M sodium hydroxide. The flask was kept at 
80 °C for 8 h, cooled to room temperature and volume was readjusted to 20 mL with 1 M 
sodium hydroxide. The solution was neutralized with 1 M hydrochloric acid solution and 
then chromatogram was recorded.  
Photodegradation of VRT 
For photodegradation studies, 10.0 mL of VRT solution (100 µg mL
−1) was taken in to 20.0 
mL volumetric flask and diluted to the mark with mobile phase. The flask was exposed to 
UV light for 8 h continuously. The experiment was also repeated with solid drug sample. 
The solutions of both were injected into liquid chromatograph separately and 
chromatograms were recorded. 
Results and Discussion 
Method Development and Optimization 
The separation and run time of RP-HPLC depends on composition of the mobile phase or 
its solvent strength. Selection of the mobile phase is very critical for developing a method 
for the separation of impurities or degradants from the drug substance. The purpose of the 
buffer to be used in mobile phase is to control the pH. The selection of buffer is based on 
pKa of the compound. Maximum pH control of the mobile phase occurs at a pH that is 
equal to the pKa of buffer salt. Since the pKa of VRT is 9.2 at 25 °C, the selection of buffer 
with specific concentration and its pH becomes important. Basic buffer was found to be not 
suitable since unsymmetrical peaks were observed. Moreover, the peaks of degradants 
and pure drugs were not separated properly.  
In the present study, symmetrical and resolved peaks were noticed with the mobile phase 
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pKa of acetate salt (buffer) is 4.8 and it has a buffering range from 2.5 to 5.5, which is 
useful to develop a robust stability-indicating method. 
Unwanted interaction between the drug substance and acidic silanol group on the surface 
of silica-based stationary phases is the major cause of poor column efficiency and 
selectivity. Fully reacted and end-capped column, Inertsil C18 was used to minimize the 
effect. Column compartment temperature was maintained at 40°C to improve resolution 
between the drug substance and degradation products.  
Tab. 1.   Gradient program 
Time (min)  Mobile phase  
A (% v/v) 
Mobile phase  
B (% v/v) 
Elution 
0.00–1.00  95  5  Isocratic 
1.00–15.00  9520  580  Linear gradient 
15.00–25.00  20  80  Isocratic 
25.00–30.00  2095  805  Linear gradient 
30.00–35.00  95  5  Re-equilibration 
 
To optimize the chromatographic conditions, the effect of composition of mobile phase, 
flow rate and the detection wavelength was investigated. Ideal chromatographic conditions 
were observed with the mobile phase consisting of ammonium acetate buffer containing 
trifluoroacetic acid (0.02 M; pH 4.0) and acetonitrile. Trifluoroacetic acid was used as a 
modifier to improve the peak symmetry and resolution. A flow rate of 1.0 mL min
−1 was 
maintained throughout the analysis in gradient elution. Based on qualitative and 
quantitative results, we have selected the detector wavelength of 237 nm in the present 
study. Typical chromatogram is shown in Fig. 2.  
Precision 
The % RSD values for intra-day and inter-day assay precision were calculated and found 
to be less than 0.7% and 0.9%, respectively,  indicating thereby that the method was 
sufficiently precise. 
Accuracy 
The % recovery values of VRT in pharmaceutical formulation ranged from 99.6 to 100.3. 
High percentage recovery values revealed that the proposed method is accurate and could 
be adopted for routine quality control. 
Limit of Detection (LOD) and Limit of Quantification (LOQ) 
The ICH guidelines were followed to calculate the values of LOD and LOQ and were 
observed to be 0.31 µg mL
−1  and 0.97 µg mL
−1,  respectively. The %RSD value was 
noticed to be less than 1.0 % at LOQ concentration level.  
Linearity 
The calibration plot revealed the linearity in the range of 0.1–192 µg mL
−1 (R
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Fig. 3.   Typical chromatograms of VRT exposed to 10 % hydrogen peroxide (a), 80°C 
(b), 1 M hydrochloric acid (c), 1 M sodium hydroxide (d) and UV light (e) 122  S. S. Pujeri, A. M. A. Khader, J. Seetharamappa:   
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Fig. 3.   (Cont.) 
Robustness 
Under all the deliberately varied chromatographic conditions (flow rate and column 
temperature), the reproducibility of results was observed to be reasonably good. Hence, 
the proposed method has good robustness for the assay of VRT in bulk or in tablets.  
Solution Stability and Mobile phase Stability 
The % RSD values for the assay of VRT during solution stability and mobile phase stability 
experiments were found to be less than 0.7 %. This indicated that the sample solutions 
and mobile phases used during the assay were stable for at least 48 h. 
Forced Degradation Studies 
Stress studies on VRT were carried out under oxidation, thermal stress, photolysis, acid 
and base hydrolysis conditions. It was found that the degradation was not observed in 
VRT sample when it was subjected to oxidation, thermal stress, acid and base hydrolysis 
(Figs. 3a, 3b, 3c and 3d). However, degradation products were found in photolysis stress 
conditions (Fig 3e).   Stress Degradation Studies on Varenicline Tartrate and Development of a Validated …  123 
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Peak purity test results confirmed that the VRT peak was homogenous and pure in all the 
analyzed stress samples. Lower purity angle value of VRT compared to that of the purity 
threshold (Table 2 and Fig. 4) revealed that the VRT was free from interference from its 
impurities and its degradants.  
 
Fig. 4.   Purity plot of VRT 
Tab. 2.   System suitability parameters 
Name  Retention  
time (min) 
Purity  
angle 
Purity  
threshold 
USP  
tailing 
USP  
Plate Count 
VRT  8.417  0.161  1.016  1.070  48670 
 
To avoid column damage at too acidic or too basic conditions generated during the stress 
studies and also to avoid peak splitting or unsymmetrical peak, the solutions were 
neutralized and chromatograms were recorded. Recovery results are shown in Table 3. 
Assay of the stressed samples was performed by comparison with reference standards 
and the mass balance (% assay + % degradation products) for stressed samples was 
calculated (Table 4). The developed HPLC method revealed that there was no interference 
from the impurities, degradation products and excipients to determine the assay of drug 
substance in pure and pharmaceutical formulation.  
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Tab. 3.   Recovery results of VRT sample 
Added (µg)
a  Recovered (µg)  % Recovery  % RSD 
50.0  49.8  99.6  0.5 
100.0  100.1  100.1  0.7 
150.0  150.4  100.3  1.2 
a Average of six determinations. 
 
Tab. 4.   Summary of forced degradation results 
Stress condition  Time (h)  % Assay of  
active Substance 
% Mass balance  
(% assay + impurity) 
Acid hydrolysis (1 M HCl) 
reflux at 80 °C 
8  99.51  99.69 
Base hydrolysis (1 M 
NaOH) reflux at 80 °C 
8  99.48  99.67 
Oxidation (10% H2O2) 
reflux at 80 °C 
8  96.46  99.70 
Thermal (80 °C)  12  99.60  99.68 
Photolysis (254 nm)  24  63.28  99.67 
 
Analysis of Pharmaceutical Preparations  
The proposed method was successfully applied to the analysis of VRT in tablet and the 
results are shown in Table 5. The low values of %RSD indicated high precision of the 
method. High percent recovery values indicated that the commonly employed excipients 
microcrystalline cellulose, anhydrous dibasic calcium phosphate, croscarmellose sodium, 
colloidal silicon dioxide, magnesium stearate, opadry® white, opadry® blue and opadry® 
clear did not interfere in the analysis of VRT in tablets.  
Tab. 5.   Analysis of VRT in pharmaceutical formulations. 
Formulation  Labeled, mg  Found
a, mg  % RSD  % Recovery 
CHANTIX®  0.5  0.49  0.89  98.0 
CHANTIX®  1.0  0.99  1.17  99.0 
a Average of nine determinations. 
 
Conclusions 
The proposed method is observed to be precise, specific, accurate and stability-indicating. 
VRT can be determined in bulk powder, pharmaceutical formulation as well as in the 
presence of its degradation products by HPLC method. ICH guidelines were followed 
throughout the study for method validation and stress testing. In view of this, the proposed 
method could be adopted for quality control and routine analysis.   Stress Degradation Studies on Varenicline Tartrate and Development of a Validated …  125 
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